NCT03204500View on ClinicalTrials.gov

Dual Treatment With Lithium and Valproate in ALS.

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

April 30, 2019

Study Completion Date

August 31, 2019

Conditions
Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis, Sporadic
Interventions
COMBINATION_PRODUCT

Active treatment with dual therapy

Blue pills ( 200 mg of magnesium valproate ) and white pills ( 300 mg of lithium carbonate) are administered orally with meals.

DRUG

Placebos

Administered orally under the same conditions

Trial Locations (1)

14269

Instituto Nacional de Neurologia Y Neurocirugia Mvs, Mexico City

All Listed Sponsors
lead

El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez

OTHER

NCT03204500 - Dual Treatment With Lithium and Valproate in ALS. | Biotech Hunter | Biotech Hunter